Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Thrombopenia increased by heparin and danaparoid].

G Godet1, M Bertrand, E Van de Steen

  • 1Département d'anesthésie-réanimation, hôpital Pitié-Salpêtrière, 75013 Paris, France. gilles.godet@psl.ap-hop-paris.fr

Annales Francaises D'Anesthesie Et De Reanimation
|March 10, 2001
PubMed
Summary

Heparin-induced thrombocytopaenia (HIT) is a known complication of heparin therapy. A rare cross-reactivity with danaparoid sodium, a heparin alternative, is highlighted in this case report.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Specific Follicular Helper T Cell Signature in Takayasu Arteritis.

Arthritis & rheumatology (Hoboken, N.J.)·2021
Same author

Development of <math> </math> -containing scintillating bolometers for a high-sensitivity neutrinoless double-beta decay search.

The European physical journal. C, Particles and fields·2020
Same author

mTOR pathway activation in large vessel vasculitis.

Journal of autoimmunity·2018
Same author

[Aortitis and surgery].

La Revue de medecine interne·2016
Same author

Takayasu Arteritis and Pregnancy.

Arthritis & rheumatology (Hoboken, N.J.)·2015
Same author

Indications to open surgical repair of the thoracic aorta in the "endovascular" era.

The Journal of cardiovascular surgery·2015

Area of Science:

  • Hematology
  • Pharmacology

Background:

  • Heparin-induced thrombocytopaenia (HIT) is a serious immune-mediated complication associated with unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH).
  • Prompt diagnosis and discontinuation of heparin are crucial for management.
  • Alternative anticoagulants are often considered for patients with HIT.

Observation:

  • This case report describes a patient who developed thrombocytopaenia while receiving danaparoid sodium (Orgaran) after a diagnosis of HIT.
  • Danaparoid sodium is a heparin derivative used as an alternative anticoagulant in HIT patients.
  • This suggests a potential cross-reactivity between heparin and danaparoid sodium.

Findings:

  • The patient experienced a recurrence of thrombocytopaenia upon administration of danaparoid sodium.

Related Experiment Videos

  • This finding indicates a possible hypersensitivity or cross-reactivity phenomenon.
  • This complication, though rare, necessitates careful consideration when selecting alternative anticoagulants.

    • Implications:

    • Clinicians should be aware of the potential for cross-reactivity between heparin products and danaparoid sodium.
    • Vigilance is required when initiating alternative anticoagulants in patients with a history of HIT.
    • Further investigation into the immunological mechanisms underlying this cross-reactivity may be warranted.